Synthetic Cannabinoids Tied to High-Risk Behavior in Adolescents

Share this content:
Synthetic Cannabinoids Tied to High-Risk Behavior in Adolescents
Synthetic Cannabinoids Tied to High-Risk Behavior in Adolescents

MONDAY, March 13, 2017 (HealthDay News) -- Adolescents who use synthetic cannabinoids are at a heightened risk for violent behavior, high-risk sexual activity, and abuse of other drugs, according to research published online March 13 in Pediatrics.

Heather Clayton, Ph.D., a health scientist at the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues collected data on 15,624 high school students. The information was collected in 2015. The participants were asked about their use of marijuana and synthetic cannabinoids. They were also asked about other drug use, violent behavior, mental health, and sexual behavior.

The researchers found that adolescents who used synthetic cannabinoids were more prone to being injured or to engage in violent behaviors than those who used only marijuana. Students who used synthetic cannabinoids also were more likely to have started using marijuana very early in life, before the age of 13, compared with students who had used only marijuana. In addition, teens who used synthetic cannabinoids were more likely to have used real marijuana 20 times or more in the past 30 days. Synthetic cannabinoid use was also linked to higher odds of having sex without a condom or other forms of birth control.

"To prevent marijuana use and the use of synthetic cannabinoids, it is important that health professionals and school-based substance prevention programs include strategies that reduce the initiation of marijuana and synthetic cannabinoid use, particularly among students younger than 13 years of age," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Ocrevus to Treat Severe Form of Multiple Sclerosis

FDA Approves Ocrevus to Treat Severe Form of ...

First drug sanctioned in United States for primary progressive multiple sclerosis

Study Explores Links Between Zika, GBS, Microcephaly in Brazil

Study Explores Links Between Zika, GBS, Microcephaly in ...

Apparent resurgence of Zika virus and GBS early in 2016, but no subsequent increase in microcephaly

Inadvertent HPV Vax Doesn't Up Risk of Poor Pregnancy Outcomes

Inadvertent HPV Vax Doesn't Up Risk of Poor ...

No increased risk of major birth defect, spontaneous abortion, preterm birth, low birth weight, SGA

is free, fast, and customized just for you!

Already a member?

Sign In Now »